At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 2.23: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
29.76BINR311.01M · vs all stocks (USD)
Revenue (TTM)
14.31BINR149.57M · vs all stocks (USD)
Profit Margin
-0.11%Beta
0.8890xvs all stocks
52-Week Change
-1.52%vs all stocks
Market Capitalization
29.76BINR311.01M · vs all stocks (USD)
Enterprise Value
36.01BINR376.30M · vs all stocks (USD)
Forward P/E
19.56xPrice to Sales (TTM)
2.07xPrice to Book (MRQ)
2.14xEnterprise to Revenue
2.52xEnterprise to EBITDA
18.97xGross Margin
48.52%Profit Margin
-0.11%Operating Margin
9.24%Return on Assets (TTM)
-0.32%Return on Equity (TTM)
-0.59%Revenue (TTM)
14.31BINR149.57M · vs all stocks (USD)
Revenue per Share (TTM)
318.10INRUpdated Aug 22, 2026Quarterly Revenue Growth
19.60%Gross Profit (TTM)
6.97BINR72.83M · vs all stocks (USD)
EBITDA (TTM)
2.00BINR20.85M · vs all stocks (USD)
Net Income (TTM)
-16.20MINR-169.27K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
55.00%Operating Cash Flow (TTM)
1.53BINR15.98M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-74.10MINR-774.27K · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
26.70MINRFY2026 · Mar 31, 2026Revenue
13.69BINRFY2026 · Mar 31, 2026Cost of Goods Sold
6.85BINRFY2026 · Mar 31, 2026Gross Profit
6.84BINRFY2026 · Mar 31, 2026Operating Income
870.70MINR9.10M · vs all stocks (USD)
Pre-tax Income
-74.10MINRFY2026 · Mar 31, 2026Income Tax Expense
0.00INRFY2026 · Mar 31, 2026Net Income
-74.10MINRFY2026 · Mar 31, 2026EBIT
873.40MINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
1.93BINRFY2026 · Mar 31, 2026Other Operating Expenses
2.79BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
947.50MINRFY2026 · Mar 31, 2026EPS (Basic)
-1.68INRFY2026 · Mar 31, 2026EPS (Diluted)
-1.68INRFY2026 · Mar 31, 2026Basic Shares Outstanding
44.11MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
44.11MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
-74.10MINRFY2026 · Mar 31, 2026Minority Interests (P&L)
0.00INRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
250.10MINRFY2026 · Mar 31, 2026Free Cash Flow
245.00MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
44.80MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-74.10MINRFY2026 · Mar 31, 2026Stock-based Compensation
46.70MINRFY2026 · Mar 31, 2026Other Non-cash Items
918.20MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-1.11BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
472.50MINRFY2026 · Mar 31, 2026Capital Expenditures
5.10MINRFY2026 · Mar 31, 2026Net Acquisitions
800.00KINRFY2026 · Mar 31, 2026Purchase of Investments
-487.00MINRFY2026 · Mar 31, 2026Other Investing Activity
10.70MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-470.40MINRFY2026 · Mar 31, 2026Long-term Debt Issuance
495.00MINRFY2026 · Mar 31, 2026Long-term Debt Payments
-888.90MINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-768.10MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
423.20MINRFY2026 · Mar 31, 2026Shares Outstanding
47.80MSharesUpdated Aug 22, 2026Float Shares
31.85MSharesUpdated Aug 22, 2026% Held by Insiders
52.24%vs all stocks
% Held by Institutions
16.67%vs all stocks
Total Cash (MRQ)
533.40MINR5.57M · vs all stocks (USD)
Total Cash per Share (MRQ)
11.51INRUpdated Aug 22, 2026Total Debt (MRQ)
6.87BINR71.74M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5468xCurrent Ratio (MRQ)
0.9599xBook Value per Share (MRQ)
287.12INRUpdated Aug 22, 2026Total Assets
23.33BINR243.73M · vs all stocks (USD)
Total Current Assets
8.58BINRFY2026 · Mar 31, 2026Total Liabilities
10.77BINRFY2026 · Mar 31, 2026Total Non-current Assets
14.74BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
1.83BINRFY2026 · Mar 31, 2026Total Current Liabilities
8.94BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
44.80MINRFY2026 · Mar 31, 2026Other Short-term Investments
554.00MINRFY2026 · Mar 31, 2026Accounts Receivable
4.39BINRFY2026 · Mar 31, 2026Inventory
3.18BINRFY2026 · Mar 31, 2026Accounts Payable
2.74BINRFY2026 · Mar 31, 2026Short-term Debt
5.57BINRFY2026 · Mar 31, 2026Other Current Liabilities
163.60MINRFY2026 · Mar 31, 2026Long-term Debt
1.30BINRFY2026 · Mar 31, 2026Common Stock (Book)
445.10MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
12.56BINR131.19M · vs all stocks (USD)
52-Week Low
422.00INRUpdated Aug 22, 202652-Week High
712.00INRUpdated Aug 22, 202652-Week Change
-1.52%vs all stocks
Beta
0.8890xvs all stocks
50-Day MA
550.86INRUpdated Aug 22, 2026200-Day MA
524.66INRUpdated Aug 22, 2026Avg 10-Day Volume
890.20KSharesUpdated Aug 22, 2026Avg 30-Day Volume
474.53KSharesUpdated Aug 22, 2026Diluted EPS (TTM)
-0.7000INRUpdated Aug 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.49Profit Margin: -0.00
Financial Health
Altman Z-Score 2.23: grey zoneSignificant
Altman Z-Score: 2.23
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eledon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule